TELESTA THERAPEUTICS INC T.TST

Competition.

[loveshackdave]

Heat Biologics HS-410 was just granted fast track designation for NMIBC. DFS rate seems to be slightly better than MCNA at 1 year (30%). Also, it looks like Roche has a drug (MPDL3280A) with breakthrough designation. How much of a lead will Telesta have when it hits the market? 3 to 4 years? I can see competition having an impact on any buyout price. I really hope the submit before the new June 30th deadline.

[DamnYankees]

Good stuff  Shack! Not enough people put the effort into figuring out this sad valuation. I am not sure whether competition was mentioned  by the analyst but I think Valstar was the only real competition in the shareholder presentation that has been seen by some current shareholders. Maybe they are overlooking all this competition and the market is not. Good due diligence!

[beechguy]

sounds interesting but still evaluating phase 1 data and partially enrolled in phase 2. They are at a minimum 6 -10 years behind MCNA. They are where we were at I'm 2006. Pretty sure that is not a big concern for investors. More likely not having faith that they won't roll out another financing. With multiple term sheets in hand, a finacing is very unlikely. I expect a partnership or a

[loveshackdave]

Heat has fully enrolled phase 2 with an expected completion date in 2016. The Roche venture has breakthrough designation and there are example of similar companies applying for approval earlier than phase III designation (see cldn). 6 years is absurdly optimistic 10 is insane. I'm not saying that this will be the death of MCNA, with DFS rates so similar, it is unlikely to replace it completely

[DamnYankees]

I probably more agree with BeachGuy. Most investors that know anything are far more concerned that the company will choose a low end fnancing over a sale or partnership than they are distant early stage competition. The best news is that if they choose a sale or partnership they will announce it which should help the share price. If a financing is the best thing for shareholder value (share price)

[beechguy]

Dave. Once the Heat phase 2 trial is complete it may take up to a year to compile data and get FDA protocol for first phase 3. The trial itself is likely 3.5 to 4 years with another year follow up. Following that like most phase 3 cancer drugs, they will require a phase 3b trial for another 4 years plus a year follow up. Finally Submission and another 10 months wait. 10 years insane ? The earliest

[RetailRube]

Hey Dave, TST's investor presentation (Feb-19 version) lists 10 competitors on page 21.  The title of the slide is "MCNA - No Late Stage Competiton."  It includes the FDA identifier for each clinical trial so you can go to the FDA website and read about the most current status for yourself.  Heat Biologics is shown in the list, but their therapy is called HS-401

[loveshackdave]

Rube, I saw the "no late stage competition" just like everyone else. HS-401 is probably a typo on Telesta's part. They named it Vesigenurtacel-L in the presentation, which is in fact HS-410 (see link https://www.heatbio.com/product-pipeline/hs-410) and also matches the clinical.gov identifier. Maybe I should email Don Olds like you suggested to let him know there is a typo in his

[RetailRube]

Dave,  I owe you an apology.  It was DamnYankee who said he hadn't read TST's investor presentation thoroughly.  You didn't say that. However, as a shareholder, it is in my best interest to tell Don Olds how he might improve his presentation.  Because my money is involved, I don't care what he thinks of me, snarky or otherwise.  Again I ask you: 

[DamnYankees]

Dismount your steed double R. Not everybody has the time or inclination for your forensic analysis. Yes I most certainly did read the Shareholder Presentation for current shareholders. I thought that is was OK. Like most current shareholders  OK then and OK in hidsight. It maybe me feel OK about owning it for a short while. You can't blame others for the crumby shareprice. Like HT advises